文献速递小儿泌尿与泌尿修复

儿童神经源性膀胱中的白蛋白尿:识别早期肾脏疾病的标志物

Albuminuria in Pediatric Neurogenic Bladder: Identifying an Earlier Marker of Renal Disease.
PubMed 文献 · Urology · 2019-08-24

本研究纳入40例儿童神经源性膀胱患者,检测导尿尿液白蛋白与肌酐比值(ACR)。约32%(13/40)患者ACR升高(≥30 mg/g),单因素分析显示ACR升高与白人种族、清洁间歇导尿、肾积水及膀胱输尿管反流相关;多因素分析中膀胱输尿管反流和抗胆碱能药物使用是ACR升高的显著预测因素。结论提示白蛋白尿可能有助于识别儿童神经源性膀胱中进展性肾病风险。

要点

  • 约32%儿童神经源性膀胱患者存在ACR升高(≥30 mg/g)。
  • 膀胱输尿管反流和抗胆碱能药物使用是ACR升高的显著预测因素。
  • 建议将ACR纳入儿童神经源性膀胱肾脏风险评估。

核心结论

  • 儿童神经源性膀胱患者中白蛋白尿常见,且与泌尿系统异常相关,提示进展性肾病风险增加。
  • 支持将ACR加入儿童神经源性膀胱的肾脏风险评估。

研究设计与样本

  • 单中心研究,纳入40例在三级儿童医院就诊的神经源性膀胱患者,采集导尿尿液检测ACR。
  • 分析ACR与估算肾小球滤过率、膀胱输尿管反流、肾积水、膀胱动力学及肾瘢痕的关联。

主要发现

  • 约32%(13/40)的神经源性膀胱患者ACR升高(≥30 mg/g)。
  • 单因素分析中,ACR升高与白人种族、清洁间歇导尿、肾积水及膀胱输尿管反流相关。
  • 多因素分析中,膀胱输尿管反流和抗胆碱能药物使用是ACR升高的显著预测因素。

关键数值与推荐

  • ACR升高定义为≥30 mg/g,40例中13例(约32%)达到该标准。

临床怎么用

  • 对儿童神经源性膀胱患者,除常规评估外可考虑检测尿ACR以辅助识别早期肾脏疾病风险。
  • 尤其对于存在膀胱输尿管反流或使用抗胆碱能药物的患者,应关注白蛋白尿情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the role of albuminuria as a clinical marker of early renal disease in children with neurogenic bladder (NGB) in association with commonly used predictors of renal risk. METHODS: Catheterized urine was obtained from 40 patients with NGB at a tertiary pediatric hospital. Albumin-to-creatinine ratio (ACR) was analyzed for associations with estimated glomerular filtration rate, vesicoureteral reflux, hydronephrosis, bladder dynamics, and renal scarring. RESULTS: About 32% (13/40) of NGB patients had elevated ACR (≥30 mg/g. Elevated ACR was associated with Caucasian race, clean intermittent catheterization, hydronephrosis, and vesicoureteral reflux on univariate analysis. In multivariable analysis, presence of vesicoureteral reflux and use of anticholinergic medication were significant predictors of ACR elevation. CONCLUSION: Albuminuria is an established clinical predictor of renal disease and risk for progression to renal failure. The presence of albuminuria in NGB patients with urinary tract abnormalities suggests these patients may be at increased risk for progressive renal disease. This supports the clinical utility of adding ACR to the evaluation of renal risk in pediatric NGB.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Millner RO, Preece J, Salvator A, et al. Albuminuria in Pediatric Neurogenic Bladder: Identifying an Earlier Marker of Renal Disease. Urology. 2019. PMID: 31454657. doi:10.1016/j.urology.2019.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。